BRCA2 and breast cancer: Approximately one‐half of HGSOCs are described as having identifiable defects in the HR pathway, with the archetypal defects being germline or somatic BRCA inactivation.3 Surprisingly, the EMSY gene, the product of which has been shown to bind and inactivate BRCA2, has received relatively little attention in HGSOC, despite being associated with a poor prognosis in individuals with breast cancer.14, 15, 18, 19, 20, 21, 22